

# Viral Conjunctivitis Treatment Pipeline Review H2 2016

*Viral Conjunctivitis Therapeutic Pipeline Market  
Review, H2 2016*

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- Summary

The report provides comprehensive information on the therapeutics under development for [Viral Conjunctivitis](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Complete Report @

<https://www.wiseguyreports.com/reports/643473-viral-conjunctivitis-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
- The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects



- The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643473-viral-conjunctivitis-pipeline-review-h2-2016>

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/643473-viral-conjunctivitis-pipeline-review-h2-2016>

#### Table of Content

Viral Conjunctivitis Overview	6
Therapeutics Development	7
Pipeline Products for Viral Conjunctivitis - Overview	7
Viral Conjunctivitis - Therapeutics under Development by Companies	8
Viral Conjunctivitis - Pipeline Products Glance	9
Clinical Stage Products	9
Early Stage Products	10
Viral Conjunctivitis - Products under Development by Companies	11
Viral Conjunctivitis - Companies Involved in Therapeutics Development	12
Adenovir Pharma AB	12
NanoViricides, Inc.	13
Panoptes Pharma Ges.m.b.H.	14
Shire Plc	15
Starpharma Holdings Limited	16
Viral Conjunctivitis - Therapeutics Assessment	17
Assessment by Monotherapy Products	17
Assessment by Target	18
Assessment by Mechanism of Action	20
Assessment by Route of Administration	22
Assessment by Molecule Type	24
Drug Profiles	25
APD-209 - Drug Profile	25
Product Description	25
Mechanism Of Action	25
R&D Progress	25
APD-514 - Drug Profile	27
Product Description	27

Mechanism Of Action 27  
R&D Progress 27  
astodrimer - Drug Profile 28  
Product Description 28  
Mechanism Of Action 28  
R&D Progress 28  
EKCCide-I - Drug Profile 32  
Product Description 32  
Mechanism Of Action 32  
R&D Progress 32  
PP-001 - Drug Profile 33  
Product Description 33  
Mechanism Of Action 33  
R&D Progress 33  
SHP-640 - Drug Profile 34  
Product Description 34  
Mechanism Of Action 34  
R&D Progress 34  
Viral Conjunctivitis - Dormant Projects 36  
Viral Conjunctivitis - Discontinued Products 37  
Viral Conjunctivitis - Product Development Milestones 38  
Featured News & Press Releases 38  
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 38  
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis 38  
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjunctivitis 39  
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 39  
Appendix 41  
Methodology 41  
Coverage 41  
Secondary Research 41  
Primary Research 41  
Expert Panel Validation 41

Buy now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=643473](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643473)

Continued...

Contact Us:  
NORAH TRENT  
Partner Relations & Marketing Manager  
sales@wiseguyreports.com  
Ph: +1-646-845-9349 (US)  
Ph: +44 208 133 9349 (UK) □

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact

the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.